Trial reportCancer2012
Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases.
Trial report in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 6 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- A systematic review of stereotactic radiosurgery for metastatic spinal sarcomas.Journal of neuro-oncology · 2025Pooled it
- Radiation therapy, radiosurgery, chemotherapy and targeted therapies for metastatic spine tumors: WFNS Spine committee recommendations.Neurosurgical review · 2024Pooled it
- Clinical evaluation, diagnosis, and decision-making for metastatic spine tumors: WFNS spine committee recommendations.Neurosurgical review · 2024Pooled it
- Efficacy and safety of different fractions in stereotactic body radiotherapy for spinal metastases: A systematic review.Cancer medicine · 2019Pooled it
- Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases.Journal of the National Cancer Institute · 2019Pooled it
- Stereotactic Body Radiotherapy for Spinal Metastases: What are the Risks and How Do We Minimize Them?Spine · 2016Pooled it
- [Value of postoperative stereotaxic body radiation therapy for spinal metastases].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Trial
- Trial
- Can the spinal instability neoplastic score prior to spinal radiosurgery predict compression fractures following stereotactic spinal radiosurgery for metastatic spinal tumor?: a post hoc analysis of prospective phase II single-institution trials.Journal of neuro-oncology · 2016Trial
- Article
- Long-Term Results of a Propensity Score Analysis Comparing 5 × 5 Gy and 10 × 3 Gy of Radiotherapy Alone for Malignant Spinal Cord Compression.Journal of clinical medicine · 2025Article
- Radiotherapy with 5 × 5 Gy for Personalized Treatment of Malignant Epidural Compression of the Myelon: Long-Term Results of the PRE-MODE Trial.Journal of personalized medicine · 2025Article
- Long term outcomes following upfront stereotactic body radiotherapy alone for spinal metastases.Journal of neuro-oncology · 2025Article
- Using Time-Staged Palliative Conventional Radiation Therapy Followed by Stereotactic Body Radiation Therapy in Malignant Epidural Extension for a Nonsurgical Candidate.Advances in radiation oncology · 2025Article
- Advanced Radiotherapy Technologies in Spine Tumors: What the Surgeon Needs to Know.Global spine journal · 2025Article
- Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention.Frontiers in endocrinology · 2025Review
- Review
- Article
- Stereotactic body radiotherapy for treatment of spinal metastasis: A systematic review of the literature.Neuro-oncology advances · 2024Review
- Re-irradiation spine stereotactic body radiotherapy following high-dose conventional radiotherapy for metastatic epidural spinal cord compression: a retrospective study.Japanese journal of radiology · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn this phase 1/2 study, the authors tested the hypothesis that single-fraction stereotactic body radiotherapy (SBRT) for previously unirradiated spinal metastases is a safe, feasible, and efficacious treatment approach.
methodsAll patients were evaluated by a multidisciplinary team. Spinal magnetic resonance imaging studies were obtained before treatment and at regular intervals to define both target volume and response to treatment. SBRT was delivered to a peripheral dose of 16 to 24 grays in a single fraction while limiting the dose to the spinal cord. Higher doses were used for renal cell histology. The National Cancer Institute Common Toxicity Criteria 2.0 and McCormick neurologic function score were used as toxicity assessment tools.
resultsIn total, 61 patients who had 63 tumors of the noncervical spine were enrolled and received SBRT between 2005 and 2010 on a prospective, phase 1/2 trial at The University of Texas M. D. Anderson Cancer Center. The mean follow-up was 20 months. The actuarial 18-month imaging local control rate for all patients was 88%, the actuarial 18-month overall survival rate for all patients was 64%, and the median survival for all patients was 30 months. No significant differences in outcomes were noted with respect to tumor histology or SBRT dose. Two patients experienced radiation adverse events (grade 3 or higher). The actuarial rate of 18-month freedom from neurologic deterioration from any cause was 82%.
conclusionsData from this phase 1/2 trial supported an expanded indication for SBRT as first-line treatment of spinal metastases in selected patients. The authors concluded that additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.